TransThera Sciences Stock Surges Over 100% Amid Clinical Trial Approval

Biotech stocks are known for their volatility, but TransThera Sciences’ recent leap has been particularly eye-catching. With 藥捷安康-B stock surging over 100%, investors are turning their attention to this clinical-stage biopharmaceutical company. The surge follows the approval of its core product, Tinengotinib, for a Phase II clinical trial in China, marking a significant milestone for the company’s growth strategy. This news has put TransThera, listed under 2617.HK, in the spotlight as it captures investor interest with its promising technology and growth potential.